AP report: FDA scientists opposed the Trump administration's move to ease peptides access
Also reported by Guardian World
Summary
The Trump administration proposed making several unproven injectable peptide drugs easier to access in the United States. Most FDA scientific staff members opposed the plan and had limited input in its development, according to six people familiar with the process.Key Facts
- The Department of Health and Human Services posted the plan online Wednesday.
- The plan covers several injectable peptides promoted for muscle building, injury healing and increased energy.
- Health Secretary Robert F. Kennedy Jr. has favored easier access to the peptides.
- FDA drug staff warned that the plan could weaken the agency’s efforts to keep unproven health products off the U.S. market.
- Six people familiar with the plan’s development described the staff opposition and limited input.
- An FDA advisory panel recommended easing access to six of seven popular peptides, according to the article’s accompanying watch item.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
